Phase I Pharmacodynamic Trial of Sequential Sunitinib With Bevacizumab in Patients With Renal Cell Carcinoma and Other Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Sunitinib (Primary) ; Bevacizumab
- Indications Lung cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 29 Jun 2012 Planned end date changed from 1 Jun 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 01 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.